Quince Therapeutics’ (QNCX) “Buy” Rating Reaffirmed at D. Boral Capital
D. Boral Capital restated their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX – Free Report) in a report issued on Friday morning,Benzinga reports. D. Boral Capital currently has a $4.00 target price on the stock. A number of other equities research analysts also recently commented on the stock. Oppenheimer began coverage on shares of […]
D. Boral Capital restated their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX – Free Report) in a report issued on Friday morning,Benzinga reports. D. Boral Capital currently has a $4.00 target price on the stock. A number of other equities research analysts also recently commented on the stock. Oppenheimer began coverage on shares of […]
